Fact based stock research
Samjin Pharmaceutical (KOSE:A005500)




Research has been discontinued. Contact us if you want research on this stock.



Samjin Pharmaceutical stock research in summary

samjinpharm.co.kr


Samjin Pharmaceutical stock research analysis by the purely financial fact-based Obermatt method on current and historical performance by investment strategy | Samjin Pharmaceutical (KOSE:A005500), Pharmaceuticals, South Korea


Latest Obermatt Ranks


Country South Korea
Industry Pharmaceuticals
Index
Size class X-Small

December 31, 2016. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock



Research History: Samjin Pharmaceutical

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
84
67
67
STOCK GROWTH RANKS
32
STOCK SAFETY RANKS
98
37
37
COMBINED STOCK RANKS
93

Last update of Combined Rank: 1-Jan-2016. Stock research history is based on the Obermatt Method. The higher the rank, the better is Samjin Pharmaceutical in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 23-Dec-2016. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Samjin Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

Financial reporting date of Growth Rank: 31-Dec-2015. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Samjin Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
53
53
63
REFINANCING
87
86
87
LIQUIDITY
95
2
3
CONSOLIDATED RANK: SAFETY
98
37
37

Financial reporting date of Safety Rank: 31-Dec-2016. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Samjin Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Samjin Pharmaceutical from December 31, 2016.